|
|
| Titles |
1993 Canadian Journal of Psychiatry Clozaril |
| Related Item |
|
| Genre |
medicine |
| Genre |
medicines (psychiatric) |
| Identifier |
cjp1993aug_sep_oct_nov_dec11 |
| Note |
For treatment-resistant schizophrenia: your best chance of breaking through. 20% of patients with schizophrenia are treatment-resistant. If your patient hasn't responded to two or more antipsychotics or has intolerable side effects, consider Clozaril. Clozaril: The antipsychotic indicated for treatment-resistant schizophrenia. Treat refractory schizophrenia with minimal extrapyramidal symptoms. Clozaril produces virtually no parkinsonian effects or dystonia. No reports of tardive dyskinesia have been attributed to Clozaril in 22 years of clinical use. Enhance the prospect of social and work integration. Clozaril provides proven symptoms management essential to positive outcomes in treatment-resistant schizophrenia. Provide the benefits of CSAN (Cloazril support and assistance network). An extensive hematological program providing support in monitoring as well as ongoing patient-management assistance. In treatment-resistant schizophrenia: Clozaril your best answer…their best hope. |
| Abstract |
Clozapine, Sandoz, A man's face is pictured; half of his face is shown to be breaking apart exposing his real face (ie. The pale mask he is "wearing" is breaking apart). Theme of contagion (order / disorder). Also includes information about a support and assistance network specifically for this drug. |
